1. Home
  2. ESTC vs GKOS Comparison

ESTC vs GKOS Comparison

Compare ESTC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elastic N.V.

ESTC

Elastic N.V.

HOLD

Current Price

$47.49

Market Cap

5.6B

Sector

Technology

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$121.78

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESTC
GKOS
Founded
2012
1998
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.0B
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
ESTC
GKOS
Price
$47.49
$121.78
Analyst Decision
Buy
Strong Buy
Analyst Count
27
14
Target Price
$94.08
$133.07
AVG Volume (30 Days)
1.5M
634.6K
Earning Date
05-28-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,483,296,000.00
$507,442,000.00
Revenue This Year
$19.06
$23.30
Revenue Next Year
$13.42
$27.43
P/E Ratio
N/A
N/A
Revenue Growth
17.04
32.33
52 Week Low
$42.05
$73.16
52 Week High
$96.07
$130.23

Technical Indicators

Market Signals
Indicator
ESTC
GKOS
Relative Strength Index (RSI) 41.84 64.01
Support Level N/A $81.54
Resistance Level $51.91 $123.09
Average True Range (ATR) 2.45 4.44
MACD 0.07 1.37
Stochastic Oscillator 53.45 92.50

Price Performance

Historical Comparison
ESTC
GKOS

About ESTC Elastic N.V.

Elastic is a software company that specializes in AI-search, observability, and security deployments. Its search division offers both traditional keyword search and vector search methods to enable more context-aware querying. The software has open-source origins but generates revenue through valuable add-ons, including simplified data orchestration and server scaling techniques.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: